Tech Company Financing Transactions
Cytrellis Biosystems Funding Round
Arch Venture Partners, Biomatics Capital Partners and Merz Pharma participated in a $28.5 million Series B funding round for Cytrellis Biosystems. The round was announced on 6/6/2018.
Transaction Overview
Company Name
Announced On
6/6/2018
Transaction Type
Venture Equity
Amount
$28,500,000
Round
Series B
Investors
Proceeds Purpose
We are pleased to complete this important financing round which will allow the company to conclude clinical studies and fund our efforts to obtain regulatory clearances, said Karen Cronholm, President and CEO of Cytrellis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
299C Washington St.
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
Cytrellis Biosystems, Inc. is a clinical stage medical technology company developing a new, proprietary class of aesthetic devices.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Karen Cronholm
Chief Financial Officer
Diane Marcou
VP - Marketing
Cathleen Alaimo
VP - R & D
Steve Gemmell
VP - Sales
Michael Williams
Browse more venture capital transactions:
Prev: 6/6/2018: SensorUp venture capital transaction
Next: 6/6/2018: Reciprocal Labs venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs